Should I buy UnitedHealth Group (UNH) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $529 (+40 %), call made on July 18, 2026, maturing on July 18, 2027 (88 d ago).
Firm-by-firm track record on UnitedHealth Group
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 80 % | +21.2 % | 10 | $373 -1% |
| Deutsche Bank | 77 % | +18.9 % | 30 | $362 -4% |
| Mizuho | 85 % | +18.4 % | 20 | $493 +31% |
| Morgan Stanley | 74 % | +15.7 % | 34 | $529 +40% |
| JP Morgan | 79 % | +14.8 % | 14 | $516 +37% |
| Oppenheimer | 65 % | +14.3 % | 17 | $500 +32% |
| Stephens & Co. | 83 % | +11.9 % | 18 | $675 +79% |
| Raymond James | 60 % | +11.2 % | 20 | $330 -13% |
✅ Reasons to believe
- 83% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
- Median price target $482, i.e. +27% from the current price ($378).
- The most reliable firm on UNH, Bernstein (100% hit rate, 4 scored calls), targets $492 (call made on May 27, 2026, maturing on May 27, 2027) (+30%) in its most recent call, and $411 (call made on April 7, 2026, maturing on April 7, 2027) (+9%) in the one coming due soonest.
- 7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.1% yield), raised for 16 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 18 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on UNH
Median target $482 (+27%) · 18 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in UnitedHealth Group now?
We won't decide for you. The facts: 83% of analysts rate it a buy, median target $482 (+27%), and Bernstein (most reliable on UNH, 100%) targets $492. Weigh that against valuation (P/E ~24). This is not personalized advice.
Is it too late to invest in UnitedHealth Group?
Not according to analysts: the median target ($482) is still +27% above the current price ($378) (most reliable on UNH: Bernstein, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is UnitedHealth Group still worth investing in?
It depends on the gap between the price ($378) and its estimated value: analysts target $482 on median (+27%), with 83% buys (most reliable on UNH: Bernstein, 100%). Cross-check with their real reliability on UNH and the cautions above. Information, not advice.
What's the main risk in buying UNH?
The consensus is not unanimous: of 18 ratings, 3 are neutral.
→ Go deeper: the full UnitedHealth Group profile (consensus, analyst reliability, price target, performance).